Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABOSTO:ATORX -3.60%39 PB Ratio is 2.59 as of Jul. 14, 2026, which is 21% below its 10-year median of 3.26. GuruFocus rates OSTO:ATORX with a GF Score™ of 39/100 and a GF Value™ of kr0.01 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,228 Biotechnology companies, Alligator Bioscience AB ranks better than 53.91% on this metric.
Alligator Bioscience AB stock PB Ratio (=2.69) is close to 2-year low of 2.55.
The historical rank and industry rank for Alligator Bioscience AB's PB Ratio or its related term are showing as below:
OSTO:ATORX'
s PB Ratio Range Over the Past 10 Years
Min: 1.34 Med: 3.26 Max: 70.91
Current: 2.59
During the past 12 years, Alligator Bioscience AB's highest PB Ratio was 70.91. The lowest was 1.34. And the median was 3.26.
OSTO:ATORX's PB Ratio is ranked better than 53.91% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs OSTO:ATORX: 2.59
During the past 3 years, the average Book Value Per Share Growth Rate was -88.80% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Alligator Bioscience AB was 106.80% per year. The lowest was -88.80% per year. And the median was -41.15% per year.
Back to Basics: PB Ratio
Alligator Bioscience AB (OSTO:ATORX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ATORX vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alligator Bioscience AB (OSTO:ATORX) has a PB Ratio of 2.59 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alligator Bioscience AB and its competitors. This is 21% below median its historical median of 3.26. Over the past decade, Alligator Bioscience AB's PB Ratio has ranged from 1.34 to 70.91. According to the industry distribution chart, Alligator Bioscience AB ranks #566 out of 1228 companies in the Biotechnology industry, placing it in the top 46.1%.
Is Alligator Bioscience AB's PB Ratio too high?
Alligator Bioscience AB's current PB Ratio of 2.59 is 21% below median its 10-year median of 3.26. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 70.91. The Biotechnology industry median PB Ratio is 2.89. Alligator Bioscience AB's value of 2.59 is 10.2% below this industry median. Based on the distribution chart, Alligator Bioscience AB ranks #566 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alligator Bioscience AB has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #566 out of 1228 companies for PB Ratio. This puts Alligator Bioscience AB in the upper half of its industry. The industry median PB Ratio is 2.89. Alligator Bioscience AB's value of 2.59 is 10.2% below this benchmark. Historically, Alligator Bioscience AB's own PB Ratio has ranged from 1.34 to 70.91 over the past decade. While the company's 10-year median is 3.26 vs. the industry median of 2.89, Alligator Bioscience AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alligator Bioscience AB's current PB Ratio of 2.59 is 10.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current PB Ratio is 2.59, which is 21% below median its own 10-year median of 3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.17 — trading 1612% above its estimated fair value. The current PB Ratio is 2.59, which is 21% below median its 10-year median of 3.26 and 10.2% below the Biotechnology industry median of 2.89. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current PB Ratio is 2.59 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?
Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued.
The current stock price of kr0.17 is trading 1612% above its estimated GF Value™ of kr0.01.
GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:ATORX:
PB Ratio: 2.59 (21% below median its 10-year median of 3.26)
GF Value™: kr0.01 vs. price of kr0.17 (1612% above fair value)
Industry Position: 10.2% below the Biotechnology median (#566 of 1228)
No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score
Get the complete analysis for OSTO:ATORX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ATORX has been successfully added to your 
